Literature DB >> 34090697

Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells.

Masashi Shingai1, Naoki Nomura2, Toshiki Sekiya3, Marumi Ohno2, Daisuke Fujikura2, Chimuka Handabile2, Ryosuke Omori2, Yuki Ohara4, Tomohiro Nishimura4, Masafumi Endo4, Kazuhiko Kimachi4, Ryotarou Mitsumata5, Tomio Ikeda5, Hiroki Kitayama6, Hironori Hatanaka6, Tomoyoshi Sobue7, Fumihito Muro7, Saori Suzuki8, Cong Thanh Nguyen8, Hirohito Ishigaki8, Misako Nakayama8, Yuya Mori8, Yasushi Itoh8, Marios Koutsakos9, Brendon Y Chua9, Katherine Kedzierska9, Lorena E Brown9, David C Jackson9, Kazumasa Ogasawara8, Yoichiro Kino10, Hiroshi Kida11.   

Abstract

Current detergent or ether-disrupted split vaccines (SVs) for influenza do not always induce adequate immune responses, especially in young children. This contrasts with the whole virus particle vaccines (WPVs) originally used against influenza that were immunogenic in both adults and children but were replaced by SV in the 1970s due to concerns with reactogenicity. In this study, we re-evaluated the immunogenicity of WPV and SV, prepared from the same batch of purified influenza virus, in cynomolgus macaques and confirmed that WPV is superior to SV in priming potency. In addition, we compared the ability of WPV and SV to induce innate immune responses, including the maturation of dendritic cells (DCs) in vitro. WPV stimulated greater production of inflammatory cytokines and type-I interferon in immune cells from mice and macaques compared to SV. Since these innate responses are likely triggered by the activation of pattern recognition receptors (PRRs) by viral RNA, the quantity and quality of viral RNA in each vaccine were assessed. Although the quantity of viral RNA was similar in the two vaccines, the amount of viral RNA of a length that can be recognized by PRRs was over 100-fold greater in WPV than in SV. More importantly, 1000-fold more viral RNA was delivered to DCs by WPV than by SV when exposed to preparations containing the same amount of HA protein. Furthermore, WPV induced up-regulation of the DC maturation marker CD86 on murine DCs, while SV did not. The present results suggest that the activation of antigen-presenting DCs, by PRR-recognizable viral RNA contained in WPV is responsible for the effective priming potency of WPV observed in naïve mice and macaques. WPV is thus recommended as an alternative option for seasonal influenza vaccines, especially for children.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inactivated whole influenza virus particle vaccine; Seasonal and pandemic influenza

Mesh:

Substances:

Year:  2021        PMID: 34090697     DOI: 10.1016/j.vaccine.2021.05.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques.

Authors:  Brendon Y Chua; Toshiki Sekiya; Marios Koutsakos; Naoki Nomura; Louise C Rowntree; Thi H O Nguyen; Hayley A McQuilten; Marumi Ohno; Yuki Ohara; Tomohiro Nishimura; Masafumi Endo; Yasushi Itoh; Jennifer R Habel; Kevin J Selva; Adam K Wheatley; Bruce D Wines; P Mark Hogarth; Stephen J Kent; Amy W Chung; David C Jackson; Lorena E Brown; Masashi Shingai; Katherine Kedzierska; Hiroshi Kida
Journal:  PLoS Pathog       Date:  2022-10-07       Impact factor: 7.464

2.  Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection.

Authors:  Chimuka Handabile; Toshiki Sekiya; Naoki Nomura; Marumi Ohno; Tomomi Kawakita; Masashi Shingai; Hiroshi Kida
Journal:  Vaccines (Basel)       Date:  2022-05-19

Review 3.  Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens.

Authors:  Lynda Coughlan; Eric J Kremer; Dmitry M Shayakhmetov
Journal:  Mol Ther       Date:  2022-01-31       Impact factor: 12.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.